TABLE I.

Five-Year EFS and OS in D9803 Study

Biologic subset	Patients (#)	EFS (95% CI)	OS
Molecular subtype
ERMS	305	77% (72%, 82%)	82% (77%, 86%)
ARMS PAX3	85	54% (43%, 65%)	64% (52%, 74%)
ARMS PAX7	23	65% (42%, 81%)	87% (64%, 96%)
ARMS negative	21	90% (65%, 97%)	89% (64%, 97%)
Stage 1 or Stage 2, 3/Group I/II
ARMS PAX3	28	65% (44%, 80%)	70% (47%, 85%)
ARMS PAX7	12	75% (41%, 91%)	92% (54%, 99%)
ARMS negative	10	100%	100%
Stage 2, 3/Group III
ERMS	261	77% (71%, 81%)	82% (77%, 86%)
ARMS PAX3	57	49% (36%, 62%)	61% (47%, 73%)
ARMS PAX7	11	55% (23%, 78%)	82% (45%, 95%)
ARMS negative	11	82% (45%, 95%)	80% (41%, 95%)